6 September 2017 SATVI marks 3000th patient screened in CORTIS HR study.
SATVI recently marked the 3 000th patient who had been screened for participation in the Correlates of Risk of TB study (CORTIS-01).
The Correlates of Risk assay, developed by UCT researchers will be used to find individuals who are at high risk of tuberculosis. COR+ participants will be randomised to be in the Treatment Group, which will receive Isoniazid and Rifapentine weekly for 12 weeks, followed by active surveillance for up to 15 months, or into the Observation group which will only have active surveillance for up to 15 months. COR- participants who are randomised into the trial will all be in the Observation group
This study is ground breaking in the fight against TB because this predictive screening tool could identify those individuals at highest risk of progression from latency to TB disease, avoiding unnecessary treatment of people who would remain healthy
Read more about the study. Click here.